Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study

Abstract

OST can be considered cost-effective vs no OST from the UK NHS/PSS perspective, with a cost per QALY well below the UK's willingness-to-pay threshold. There were only small differences between BMT and MMT. The availability of two or more cost-effective options is beneficial to retaining patients in OST programs. From a societal perspective, OST is estimated to save over £14,032 and £17,174 per year for BMT and MMT vs no OST, respectively, due to savings in victim costs. Further work is required to fully quantify the clinical and health economic impacts of different OST formulations and their societal impact over the long-term.

<p>Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements</p>

“…One study in Sweden highlighted reduced criminality/victimization costs and lower direct medical costs driven by reduced emergency and hospital services. 35 This analytical method was consistent with a previously validated approach 24,26 based on two subpopulations (engaged in treatment, never in or no longer engaged with treatment). This study included a subdivision of the "engaged in treatment" subpopulation, based on choice to use additional opioids "on top" of treatment regimens (as defined by positive urine drug results).…”

“…Budget impact was assessed using a decision-tree model from a healthcare system perspective based on previous work. [24][25][26] The model was prepared to compare direct costs and indirect costs of OUD care for a standard population in two scenarios: existing standard of care, or with the introduction of PRB.…”

“…Evidence describing costs was identified from published sources or local records. 24,26 Costs to provide care at weekly intervals were calculated and summed for the year based on distributions of subpopulations. Subpopulations were defined according to behavior, persons who were: 1) engaged with treatment, no additional opioid use; 2) engaged with treatment, additional opioid use present; and 3) never in or no longer engaged with treatment, other opioid use continues.…”

Enzymatic assay for urine lactose in the assessment of recent intravenous abuse of buprenorphine

“…Opioid maintenance treatment (OMT) aims at preventing or significantly reducing illicit opioid abuse, drug-related crimes, intravenous substance abuse, and risks associated with overdose. [1][2][3][4] It enables the treatment of opioid dependence and improves patients' psychosocial welfare. 1 The need for efficient OMT has been emphasized lately, especially in the context of the opioid crisis in the United States.…”

“…Opioid maintenance treatment (OMT) aims at preventing or significantly reducing illicit opioid abuse, drug‐related crimes, intravenous substance abuse, and risks associated with overdose . It enables the treatment of opioid dependence and improves patients' psychosocial welfare .…”